A1C Reductions and Improved Patient-Reported Outcomes Following CGM Initiation in Insulin-Managed T2D
At the American Diabetes Association 80th Scientific Sessions, researchers from Dexcom presented the latest findings on a study of the Dexcom G6 Continuous Glucose Monitoring (CGM) System. The research looked at glycemic and quality of life indicators for a cohort of 39 commercially insured adults with T2D (age 25-65)* who were managed with intensive insulin therapy and used CGM for at least 12 weeks. Watch the five-minute poster presentation below.
Related Content
The efficacy and safety of the Control-IQ hybrid closed-loop system, powered by Dexcom G6, was evaluated in a multi-centered, randomized, and unblinded study.1 The researchers randomized 168...
Two recently published randomized control trials (RCTs) show the value of Dexcom Continuous Glucose Monitoring (CGM) Systems for teens and young adults with type 1 diabetes (T1D). Both trials’...